Pancreatic cancer's notorious resistance to treatment may stem from evolutionary complexities that traditional tumor analysis methods have been missing entirely. By examining individual cancer cells rather than bulk tissue samples, researchers are uncovering a far more nuanced picture of how these deadly tumors develop and adapt. The single-cell approach analyzed 137,491 individual nuclei from 24 pancreatic tumors, revealing that driver gene mutations occur at much higher frequencies than bulk sequencing studies have indicated. Most of these critical alterations manifest as copy number changes rather than simple point mutations, explaining much of the spatial variation observed within tumors. This cellular heterogeneity has profound implications for targeted therapies, particularly KRAS inhibitors which have shown promise but inconsistent results in pancreatic cancer treatment. The research demonstrates that even tumors with identical KRAS mutations may exhibit varying dependencies on this oncogene, suggesting that response to KRAS-targeted drugs could be more variable than anticipated. For patients with hereditary BRCA2 mutations, the study reveals diverse mechanisms by which the healthy copy of the gene becomes inactivated, creating distinct evolutionary paths that could influence treatment sensitivity. Perhaps most significantly, the analysis shows that tumors disable their response to transforming growth factor-beta through multiple pathways, and this occurs specifically during the transition to invasive, metastatic disease. This finding represents a potential therapeutic window - if TGF-beta pathway disruption is essential for metastasis, targeting this process could prevent cancer spread. The single-cell resolution approach fundamentally changes our understanding of pancreatic cancer evolution from a linear progression to a branching, adaptive process where different cellular populations within the same tumor may respond differently to treatments.